Daclatasvir vs telaprevir plus peginterferon alfa/ribavirin for hepatitis C virus genotype 1

Figure 2 Safety secondary endpoints in GT1b-infected patients (first 12 wk). mITT analysis (patients with missing data at posttreatment week 12 were considered failures). ¹Superior at the 5% significance level; upper bound of the 95%CI was 0%; ²One patient in the TVR arm had no measurement due to discontinuation prior to on-treatment laboratory assessment; ³Includes rash-related SAEs, AEs leading to discontinuation, and grade 3 or 4 AEs. AE: Adverse event; CI: Confidence interval; DCV: Daclatasvir; GT: Genotype; Hgb: Hemoglobin; pegIFN: Peginterferon alfa-2a; RBV: Ribavirin; SAE: Serious adverse event; TVR: Telaprevir.